OTCMKTS:RGBP Regen BioPharma (RGBP) Stock Price, News & Analysis → Shocking: One AI startup's revenue could surge 4,735% (From Manward Press) (Ad) Free RGBP Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range0.57▼0.9152-Week Range N/AVolume9,500 shsAverage Volume16,825 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartFinancialsHeadlinesSEC FilingsShort Interest Get Regen BioPharma alerts: Email Address Ad Paradigm PressNever use this word on your phone (FBI could be watching)This report sent a chill down my spine. Turns out, as part of their Jan. 6th investigation, the Feds are flagging Americans who typed these ordinary words as part of their banking transactions...Watch my unredacted video about what I think is coming next right here About Regen BioPharma Stock (OTCMKTS:RGBP)Regen BioPharma, Inc. focuses on the development of regenerative medical applications in the United States. It engages in identifying small molecules that inhibit or express NR2F6 leading to immune cell activation for oncology applications, and immune cell suppression for autoimmune disease. The company is involved in the development of its products, and therapies, including HemaXellarate, a cellular therapeutic product of autologous stromal vascular fraction derived from adipose tissue; dCellVax, an autologous dendritic cell which is treated with an siRNA inhibitor of indoleamine-2,3-dioxygenase; tCellVax which is treated with siRNA to inhibit NR2F6 and the cells re-infused to the patient; DiffronC, uses proprietary siRNA in vivo to inhibit cancer growth and activate T cells; and DuroCAR comprising of CAR-T cells which is treated with an shRNA targeting the gene NR2F6. The company was incorporated in 2012 and is based in La Mesa, California.Read More Ad Paradigm PressNever use this word on your phone (FBI could be watching)This report sent a chill down my spine. Turns out, as part of their Jan. 6th investigation, the Feds are flagging Americans who typed these ordinary words as part of their banking transactions...Watch my unredacted video about what I think is coming next right here RGBP Stock News HeadlinesApril 3, 2024 | finance.yahoo.comPresenting on the Emerging Growth Conference 69 Day 2 on April 4 Register NowApril 2, 2024 | finance.yahoo.comRegen BioPharma, Inc. to Discuss Plans to Move Forward with HemaXellerate into Clinical Phase 1 at the Emerging Growth Conference on April 4, 2024May 6, 2024 | Paradigm Press (Ad)Never use this word on your phone (FBI could be watching)This report sent a chill down my spine. Turns out, as part of their Jan. 6th investigation, the Feds are flagging Americans who typed these ordinary words as part of their banking transactions...March 5, 2024 | finance.yahoo.comRegen BioPharma, Inc. to Present at the Emerging Growth Conference on March 7, 2024March 1, 2024 | seekingalpha.comRGBPP Regen BioPharma, Inc. PFD SER A NEWFebruary 25, 2024 | benzinga.comRegen BioPharma Stock (OTC:RGBP) Earnings Dates and Earning CallsFebruary 24, 2024 | benzinga.comRegen BioPharma Stock (OTC:RGBP), Short Interest ReportFebruary 10, 2024 | msn.comRegen Biopharma Files Patent for Blood Recovery TreatmentMay 6, 2024 | Paradigm Press (Ad)Never use this word on your phone (FBI could be watching)This report sent a chill down my spine. Turns out, as part of their Jan. 6th investigation, the Feds are flagging Americans who typed these ordinary words as part of their banking transactions...February 5, 2024 | finance.yahoo.comRegen BioPharma, Inc. to Present at the Emerging Growth Conference on February 7, 2024January 9, 2024 | finance.yahoo.comPresenting on the Emerging Growth Conference 66 Day 1 on January 10 Register NowJanuary 8, 2024 | finance.yahoo.comRegen BioPharma, Inc. to Present at the Emerging Growth Conference on January 10, 2024December 29, 2023 | bbc.comYeovil Refresh team asks for patience over town regenerationDecember 5, 2023 | finance.yahoo.comRegen BioPharma, Inc. to Present at the Emerging Growth Conference on December 7, 2023November 16, 2023 | finance.yahoo.comRegen BioPharma, Inc. Selects Contract Research Organization to Assist in DuraCAR ExperimentsNovember 14, 2023 | finance.yahoo.comRegen BioPharma, Inc. CEO Outlines Future Steps in CAR T ProgramOctober 30, 2023 | finance.yahoo.comRegen BioPharma, Inc. to Discuss Confirmation Study Results on Its DuraCar Program at the Emerging Growth Conference on November 1, 2023October 25, 2023 | finance.yahoo.comRegen BioPharma, Inc. Receives Second Phase Confirmatory Data on its Duracar CAR-T Cell Therapy ProgramOctober 18, 2023 | finance.yahoo.comRegen BioPharma, Inc. Expects Second Phase of Confirmatory Study ShortlyOctober 10, 2023 | finance.yahoo.comRegen BioPharma, Inc. Receives First Phase of Confirmatory StudyOctober 4, 2023 | finance.yahoo.comGoldman Small Cap Research Publishes New Research Report on Regen BioPharma, Inc.October 3, 2023 | finance.yahoo.comRegen BioPharma, Inc. to Present at the Emerging Growth Conference on October 5, 2023September 21, 2023 | barrons.comRegen BioPharma Inc. Non-Cum. Pfd. Series ASeptember 19, 2023 | finance.yahoo.comStudies On Regen BioPharma, Inc.'s DURACAR Indicate Potential Suppression Of Autoimmunity, Company Retains Contract Research Organization To Conduct Additional Confirmatory StudiesSeptember 6, 2023 | finance.yahoo.comRegen BioPharma, Inc. to Present at the Emerging Growth Conference on September 6, 2023August 8, 2023 | finance.yahoo.comRegen BioPharma, Inc. to Present at the Emerging Growth Conference on August 10, 2023March 23, 2023 | bbc.co.ukCase study - urban regeneration in Stratford, LondonSee More Headlines Receive RGBP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Regen BioPharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:RGBP CUSIPN/A CIK1589150 Webwww.regenbiopharmainc.com Phone(619) 722-5505FaxN/AEmployees1Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. David Raymond Koos DBA (Age 63)Ph.D., Chairman, CEO, President, Secretary & Treasurer Comp: $10.05kKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFAdociaOTCMKTS:ADOIFView All Competitors RGBP Stock Analysis - Frequently Asked Questions Are investors shorting Regen BioPharma? Regen BioPharma saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 4,500 shares, an increase of 400.0% from the March 31st total of 900 shares. Based on an average daily trading volume, of 37,100 shares, the days-to-cover ratio is presently 0.1 days. View Regen BioPharma's Short Interest. When did Regen BioPharma's stock split? Regen BioPharma's stock reverse split on the morning of Monday, March 6th 2023. The 1-1500 reverse split was announced on Monday, March 6th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, March 6th 2023. An investor that had 100 shares of stock prior to the reverse split would have 0 shares after the split. How do I buy shares of Regen BioPharma? Shares of RGBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:RGBP) was last updated on 5/6/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsShocking: One AI startup's revenue could surge 4,735%Manward PressThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldCould Your Accounts Be Frozen?Allegiance GoldHe Is Giving Away BitcoinCrypto Swap ProfitsDollar CancelledLear CapitalElon to Transform U.S. Economy? Porter & CompanyForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Regen BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
